KR20220128350A - Parp 억제제와 조합되는 atr 억제제의 용도 - Google Patents

Parp 억제제와 조합되는 atr 억제제의 용도 Download PDF

Info

Publication number
KR20220128350A
KR20220128350A KR1020227023568A KR20227023568A KR20220128350A KR 20220128350 A KR20220128350 A KR 20220128350A KR 1020227023568 A KR1020227023568 A KR 1020227023568A KR 20227023568 A KR20227023568 A KR 20227023568A KR 20220128350 A KR20220128350 A KR 20220128350A
Authority
KR
South Korea
Prior art keywords
optionally substituted
cancer
alkyl
carcinoma
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227023568A
Other languages
English (en)
Korean (ko)
Inventor
마리아 쾰러
미할 짐머만
앤 롤스톤
Original Assignee
리페어 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리페어 세라퓨틱스 인크. filed Critical 리페어 세라퓨틱스 인크.
Publication of KR20220128350A publication Critical patent/KR20220128350A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227023568A 2019-12-11 2020-12-11 Parp 억제제와 조합되는 atr 억제제의 용도 Withdrawn KR20220128350A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946876P 2019-12-11 2019-12-11
US62/946,876 2019-12-11
PCT/US2020/064662 WO2021119523A1 (en) 2019-12-11 2020-12-11 Use of atr inhibitors in combination with parp inhibitors

Publications (1)

Publication Number Publication Date
KR20220128350A true KR20220128350A (ko) 2022-09-20

Family

ID=76316464

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227023568A Withdrawn KR20220128350A (ko) 2019-12-11 2020-12-11 Parp 억제제와 조합되는 atr 억제제의 용도

Country Status (12)

Country Link
US (2) US20210177856A1 (https=)
EP (1) EP4072551A4 (https=)
JP (1) JP2023506787A (https=)
KR (1) KR20220128350A (https=)
CN (1) CN115103677A (https=)
AU (1) AU2020402108A1 (https=)
BR (1) BR112022011426A2 (https=)
CA (1) CA3164203A1 (https=)
CL (1) CL2022001540A1 (https=)
IL (1) IL293810A (https=)
MX (1) MX2022007163A (https=)
WO (1) WO2021119523A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
BR112023024942A2 (pt) * 2021-06-16 2024-02-15 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
CN119212710A (zh) * 2022-04-07 2024-12-27 修复治疗公司 使用atr抑制剂的方法
US20250352539A1 (en) * 2022-06-15 2025-11-20 Astrazeneca Ab Combination therapy for treating cancer
WO2024164089A1 (en) * 2023-02-09 2024-08-15 Repare Therapeutics Inc. Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
CN117159725B (zh) * 2023-04-06 2024-07-05 上海交通大学医学院附属仁济医院 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法
WO2024243078A1 (en) * 2023-05-19 2024-11-28 Leapfrog Bio, Inc. Hsp90 inhibitors for the treatment of cancer
EP4716756A1 (en) * 2023-05-23 2026-04-01 The Francis Crick Institute Limited Targets for treatment of alt-positive cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
US11660301B2 (en) * 2017-02-24 2023-05-30 Bayer Pharma Aktiengesellschaft Combination of ATR kinase inhibitors with PARP inhibitors
AU2019373416A1 (en) * 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체

Also Published As

Publication number Publication date
MX2022007163A (es) 2022-08-25
AU2020402108A1 (en) 2022-07-14
WO2021119523A8 (en) 2021-08-05
EP4072551A4 (en) 2023-11-15
BR112022011426A2 (pt) 2022-08-30
IL293810A (en) 2022-08-01
US20240350505A1 (en) 2024-10-24
CA3164203A1 (en) 2021-06-17
CL2022001540A1 (es) 2023-01-13
EP4072551A1 (en) 2022-10-19
CN115103677A (zh) 2022-09-23
WO2021119523A1 (en) 2021-06-17
JP2023506787A (ja) 2023-02-20
US20210177856A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
KR20220128350A (ko) Parp 억제제와 조합되는 atr 억제제의 용도
CA3222841A1 (en) Use of atr inhibitors in combination with parp inhibitors for treating cancer
US12264155B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
US20220185809A1 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
US20170259081A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US20080146653A1 (en) Synergistic anti-cancer compositions
US20250228862A1 (en) Methods of using atr inhibitors
WO2017051251A1 (en) 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
EP3256115A2 (en) Combination cancer therapy
AU2003251942A1 (en) Combination of chemotherapeutic drugs for increasing antitumor activity
CN107207510A (zh) 联合疗法
WO2024164089A1 (en) Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
HK40079144A (en) Use of atr inhibitors in combination with parp inhibitors
US20250090539A1 (en) Combination treatment of cancers
RU2415672C2 (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
WO2025181153A1 (en) Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2022216930A1 (en) Novel mda-9 antagonist with anti-metastatic potential
HK40107484A (zh) Atr抑制剂与parp抑制剂的组合用於治疗癌症的用途
CN117500506A (zh) Atr抑制剂与parp抑制剂的组合用于治疗癌症的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220708

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20241211

WITB Written withdrawal of application